Jawl-Shan Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jawl-Shan Hwang has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Hsing Wu
Department of Family Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
5 shared publications Ho-Min Chen
Health Data Research Center, National Taiwan University, Taipei, Taiwan
5 shared publicationsChih-Hsing Wu
Institute of Gerontology, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Family Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
4 shared publications- Chun-Feng Huang
Department of Family Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan
4 shared publications Jou-Wei Lin
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Douliu, Yunlin County, Taiwan
4 shared publicationsYin-Fan Chang
Department of Family Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
4 shared publications
Latest Publications
- Open Access
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 3-10
Asia-Pacific consensus on long-term and sequential therapy for osteoporosis
- 16 March 2024
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 10 (1) , 3-10
Open AccessAsia-Pacific consensus on long-term and sequential therapy for osteoporosis
- Open Access
- 11 August 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S92-S100
Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis
- 11 August 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S92-S100
Open AccessCost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis
- Open Access
- 12 July 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S74-S81
Osteoporosis care after hip fracture: Observation from national health insurance database and fracture liaison services
- 12 July 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S74-S81
Open AccessOsteoporosis care after hip fracture: Observation from national health insurance database and fracture liaison services
- Open Access
- 4 June 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S36-S44
Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018
- 4 June 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S36-S44
Open AccessEleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018
- Open Access
- 2 June 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S45-S54
Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference
- 2 June 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S45-S54
Open AccessConstraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference
- Open Access
- 17 May 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S21-S35
Epidemiology and clinical impact of osteoporosis in Taiwan: A 12-year trend of a nationwide population-based study
- 17 May 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S21-S35
Open AccessEpidemiology and clinical impact of osteoporosis in Taiwan: A 12-year trend of a nationwide population-based study
- Open Access
- 27 April 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S65-S73
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
- 27 April 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S65-S73
Open AccessRefracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
- Open Access
- 11 February 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S4-S13
Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update
- 11 February 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122, S4-S13
Open AccessClinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update
- 1 November 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (4) , 827-833
Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study
Context: Osteoporosis is becoming a global epidemic in aging societies. Anti-osteoporotic medications can prevent fractures, and their pleiotropic effect on mortality is interesting but not well compared among each other.Objective: To provide real-world evidence on the pleiotropic effect of different anti-osteoporotic medications on all-cause mortality, stratified by fracture site, sex, and age.Methods: This longitudinal population-based postfracture cohort study, included mega-data from subjects ≥40 years of age with osteoporotic fracture who used anti-osteoporotic medications as recorded in Taiwan's National Health Insurance Research Database from 2009 to 2017 and followed until 2018. A multivariate Cox proportional hazards model with immortal time bias was used to assess the relationship between fracture sites and mortality stratified by anti-osteoporosis medication.Results: A total of 46 729 subjects with an average age of 74.45 years (80.0% female) and a mean follow-up period of 4.73 years were enrolled. In the total fracture group, compared with raloxifene and bazedoxifene, we found that alendronate/risedronate (hazard ratio [HR] 0.83; 95% CI, 0.79-0.88), denosumab (HR 0.86; 95% CI, 0.81-0.91), and zoledronic acid (HR 0.78; 95% CI, 0.73-0.84) resulted in significantly lower mortality. Similar trends were observed in the hip, vertebral, or nonhip/nonvertebral fracture groups. Subjects receiving long-acting zoledronic acid showed the lowest mortality in the subanalysis according to sex or age over 65 years.Conclusion: This real-world mega-data study suggests that the usage of osteoporotic medication, especially a long-acting regimen, may lower postfracture mortality.
- 1 November 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (4) , 827-833
Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study
Context: Osteoporosis is becoming a global epidemic in aging societies. Anti-osteoporotic medications can prevent fractures, and their pleiotropic effect on mortality is interesting but not well compared among each other.Objective: To provide real-world evidence on the pleiotropic effect of different anti-osteoporotic medications on all-cause mortality, stratified by fracture site, sex, and age.Methods: This longitudinal population-based postfracture cohort study, included mega-data from subjects ≥40 years of age with osteoporotic fracture who used anti-osteoporotic medications as recorded in Taiwan's National Health Insurance Research Database from 2009 to 2017 and followed until 2018. A multivariate Cox proportional hazards model with immortal time bias was used to assess the relationship between fracture sites and mortality stratified by anti-osteoporosis medication.Results: A total of 46 729 subjects with an average age of 74.45 years (80.0% female) and a mean follow-up period of 4.73 years were enrolled. In the total fracture group, compared with raloxifene and bazedoxifene, we found that alendronate/risedronate (hazard ratio [HR] 0.83; 95% CI, 0.79-0.88), denosumab (HR 0.86; 95% CI, 0.81-0.91), and zoledronic acid (HR 0.78; 95% CI, 0.73-0.84) resulted in significantly lower mortality. Similar trends were observed in the hip, vertebral, or nonhip/nonvertebral fracture groups. Subjects receiving long-acting zoledronic acid showed the lowest mortality in the subanalysis according to sex or age over 65 years.Conclusion: This real-world mega-data study suggests that the usage of osteoporotic medication, especially a long-acting regimen, may lower postfracture mortality.
- Open Access
- 8 May 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (9) , 3282
Prediction of Diabetic Nephropathy from the Relationship between Fatigue, Sleep and Quality of Life
Fatigue and poor sleep quality are the most common clinical complaints of people with diabetes mellitus (DM). These complaints are early signs of DM and are closely related to diabetic control and the presence of complications, which lead to a decline in the quality of life. Therefore, an accurate measurement of the relationship between fatigue, sleep status, and the complication of DM nephropathy could lead to a specific definition of fatigue and an appropriate medical treatment. This study recruited 307 people with Type 2 diabetes from two medical centers in Northern Taiwan through a questionnaire survey and a retrospective investigation of medical records. In an attempt to identify the related factors and accurately predict diabetic nephropathy, we applied hybrid research methods, integrated biostatistics, and feature selection methods in data mining and machine learning to compare and verify the results. Consequently, the results demonstrated that patients with diabetic nephropathy have a higher fatigue level and Charlson comorbidity index (CCI) score than without neuropathy, the presence of neuropathy leads to poor sleep quality, lower quality of life, and poor metabolism. Furthermore, by considering feature selection in selecting representative features or variables, we achieved consistence results with a support vector machine (SVM) classifier and merely ten representative factors and a prediction accuracy as high as 74% in predicting the presence of diabetic nephropathy.
- 8 May 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (9) , 3282
Open AccessPrediction of Diabetic Nephropathy from the Relationship between Fatigue, Sleep and Quality of Life
Fatigue and poor sleep quality are the most common clinical complaints of people with diabetes mellitus (DM). These complaints are early signs of DM and are closely related to diabetic control and the presence of complications, which lead to a decline in the quality of life. Therefore, an accurate measurement of the relationship between fatigue, sleep status, and the complication of DM nephropathy could lead to a specific definition of fatigue and an appropriate medical treatment. This study recruited 307 people with Type 2 diabetes from two medical centers in Northern Taiwan through a questionnaire survey and a retrospective investigation of medical records. In an attempt to identify the related factors and accurately predict diabetic nephropathy, we applied hybrid research methods, integrated biostatistics, and feature selection methods in data mining and machine learning to compare and verify the results. Consequently, the results demonstrated that patients with diabetic nephropathy have a higher fatigue level and Charlson comorbidity index (CCI) score than without neuropathy, the presence of neuropathy leads to poor sleep quality, lower quality of life, and poor metabolism. Furthermore, by considering feature selection in selecting representative features or variables, we achieved consistence results with a support vector machine (SVM) classifier and merely ten representative factors and a prediction accuracy as high as 74% in predicting the presence of diabetic nephropathy.